EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib ...

As part of the AD Up study -- a phase 3 placebo-controlled trial -- 901 adults and adolescents with moderate-to-severe AD were randomized 1:1:1 to receive once-daily upadacitinib 15 mg ...

From the March/April 2025 issue of Car and Driver. You'd think the sight of a new MG might attract more attention, whether it was spied carving up the winding roads of rural Scotland or whizzing ...

Patients who were systemic therapy-naïve and received upadacitinib 15 mg or 30 mg and those who were systemic therapy-experienced and received upadacitinib 30 mg experienced sustained effectiveness ...

Is the MG4 a good car? Small electric cars have historically been expensive, but the MG4 marked the beginning of price parity with more traditionally powered hatchbacks. But it isn't just the ...

As with other drugs, Rinvoq (upadacitinib) can cause side effects, such as upper respiratory infections, fever, and nausea. If you are not able to tolerate Rinvoq’s side effects, talk with your ...

Background: Upadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are ...